Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji1 Macromolecular Crystallography Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USACorrespondence[email protected]

Ajai Pal2 Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Ravi Kalathur1 Macromolecular Crystallography Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

Xun Hu2 Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Yijun Gu1 Macromolecular Crystallography Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA;2 Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Joseph E Saavedra3 Basic Research Program, SAIC-Frederick Inc., Frederick, MD 21702, USA

Gregory S Buzard3 Basic Research Program, SAIC-Frederick Inc., Frederick, MD 21702, USA

Aloka Srinivasan4 Laboratory of Comparative Carcinogenesis, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

Larry K Keefer4 Laboratory of Comparative Carcinogenesis, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

Shivendra V Singh2 Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

show all

Structure-based design of anticancer prodrug PABA/NO

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Structure-based design of anticancer prodrug PABA/NO

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date